The European Respiratory Society (ERS) has published guidelines for the management of adult bronchiectasis, addressing the investigation, treatment, and long-term management of this chronic condition. The guidelines are based on a systematic review of the literature and were developed by a multidisciplinary panel of experts in respiratory medicine, microbiology, physiotherapy, and other relevant fields. The guidelines focus on key clinical questions related to the management of bronchiectasis, including the investigation of underlying causes, treatment of exacerbations, pathogen eradication, long-term antibiotic treatment, anti-inflammatory and mucoactive drugs, bronchodilators, surgical treatment, and respiratory physiotherapy. The guidelines recommend standardized testing for the cause of bronchiectasis, including differential blood count, serum immunoglobulins, and testing for allergic bronchopulmonary aspergillosis (ABPA). For acute exacerbations, a 14-day course of systemic antibiotics is recommended. Eradication treatment is suggested for patients with a new isolate of P. aeruginosa, while no eradication treatment is recommended for other pathogens. Long-term anti-inflammatory agents, such as inhaled corticosteroids and statins, are not recommended for bronchiectasis due to limited evidence of benefit and potential adverse effects. Long-term antibiotic treatment is recommended for patients with three or more exacerbations per year, particularly those with chronic P. aeruginosa infection. Macrolides may be used as an alternative in cases where inhaled antibiotics are not feasible. Long-term mucoactive treatment is suggested for patients with bronchiectasis, though evidence is limited. The guidelines also emphasize the importance of respiratory physiotherapy, airway clearance, and patient education. The recommendations are based on the GRADE approach, which assesses the quality of evidence and the strength of recommendations. The guidelines aim to improve the quality of care for patients with bronchiectasis across Europe and to enhance patient outcomes.The European Respiratory Society (ERS) has published guidelines for the management of adult bronchiectasis, addressing the investigation, treatment, and long-term management of this chronic condition. The guidelines are based on a systematic review of the literature and were developed by a multidisciplinary panel of experts in respiratory medicine, microbiology, physiotherapy, and other relevant fields. The guidelines focus on key clinical questions related to the management of bronchiectasis, including the investigation of underlying causes, treatment of exacerbations, pathogen eradication, long-term antibiotic treatment, anti-inflammatory and mucoactive drugs, bronchodilators, surgical treatment, and respiratory physiotherapy. The guidelines recommend standardized testing for the cause of bronchiectasis, including differential blood count, serum immunoglobulins, and testing for allergic bronchopulmonary aspergillosis (ABPA). For acute exacerbations, a 14-day course of systemic antibiotics is recommended. Eradication treatment is suggested for patients with a new isolate of P. aeruginosa, while no eradication treatment is recommended for other pathogens. Long-term anti-inflammatory agents, such as inhaled corticosteroids and statins, are not recommended for bronchiectasis due to limited evidence of benefit and potential adverse effects. Long-term antibiotic treatment is recommended for patients with three or more exacerbations per year, particularly those with chronic P. aeruginosa infection. Macrolides may be used as an alternative in cases where inhaled antibiotics are not feasible. Long-term mucoactive treatment is suggested for patients with bronchiectasis, though evidence is limited. The guidelines also emphasize the importance of respiratory physiotherapy, airway clearance, and patient education. The recommendations are based on the GRADE approach, which assesses the quality of evidence and the strength of recommendations. The guidelines aim to improve the quality of care for patients with bronchiectasis across Europe and to enhance patient outcomes.